of Toll-like Receptors (TLR) are based on synthetic DNA and have been created through extensive structure-activity relationship studies.
The Competitive Intelligence Report Cannabinoid-1 (CB1) Receptor Antagonists
as of November 2008 provides a competitor analysis in the development pipeline of novel CB1 receptor antagonists
for treatment of obesity, type 2 diabetes and CNS diseases.
The Company was formed in 2003 and has the exclusive rights to LNA technology, a third generation antisense chemistry used to develop new classes of RNA medicines, called RNA antagonists
and microRNA antagonists
Results presented at Annual Scientific Meeting of the Obesity Society indicate Jenrin CB1 antagonists
could play a role in treatment of metabolic disorders while reducing risks of psychiatric side effects
of Toll-Like Receptors: Insights Into the Mechanism of Action" by Lakshmi Bhagat, Ph.
The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists
provides a competitor analysis in the development pipeline of novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like receptors TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 for treatment of cancer, infectious diseases, sepsis and allergy.
The Competitive Intelligence Report Integrin Antagonists
as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of a series of indications such as Crohn's disease, multiple sclerosis, acute coronary syndrome, cancer, AMD, rheumatoid arthritis.
The Competitive Intelligence Report Muscarinic Receptor Agonists & Antagonists
as of November 2007 provides a competitor analysis in the development pipeline of novel Muscarinic Receptor Agonists & Antagonists
for the treatment of cognitive impairment, overactive bladder or urinary incontinence and chronic obstructive pulmonary disease (COPD).
The results of the study suggest that TLR antagonists
may have potential in the treatment of lung inflammatory diseases.
On the other hand, GnRH antagonists
bind to GnRH receptors with high affinity.
Aprepitant belongs to a class of agents known as NK1 receptor antagonists
, which are often used in combination with 5-HT3 receptor antagonists
for the prevention of CINV.
The exact impact of these protocols has been controversial following early reports that GnRH antagonists
were associated with lower pregnancy rates.
have several advantages over GnRH agonists.
The receptor antagonists
are administered along with a 5-HT3 receptor antagonist
for the prevention of chemotherapy induced nausea and vomiting.
In one report, aldosterone antagonists
failed to improve mortality or reduce CV readmissions in patients who had heart failure with decreased ejection fraction, after clinical trials had indicated the agents would do so.